Abstract
Haemophilia B, a deficiency in clotting factor IX (FIX), occurs in about 1 in 25.000 males. Of these patients, approximately 40% are characterized as having severe haemophilia (FIX below 1% of normal). Although the use of plasma-derived or rFIX has extended the lifespan of these patients, they remain afflicted by a variety of sequelae of the disease. Interestingly, a relatively small increase in the levels of FIX results in a dramatic increase in the quality of life, requiring rFIX substitution only prior to dental and surgical procedures. This latter trait of the disease suggests that gene therapy only needs to achieve modest expression and makes this disease a prime candidate for proof-of-concept of gene therapy. Current protocols for gene therapy entail the risk of malignant transformation. In addition the viral vectors may cause substantial pathology. Hence, the field requires the development of inherently safe gene therapy. Recently, developed protocols have been developed to transduce peripheral blood cells with high efficiency using RNA as a vector. These protocols in which the inherently safe RNA-based gene therapy approach will be validated and implemented for haemophilia B will provide in turn providing important proof-of concept for this type of therapy for more prevalent diseases but requires optimization of this strategy, probably by enhancing RNA stability using artificial nucleotides and modified UTRs, enhanced production of protein by codon usage optimization and the use of multi-cistronic constructs, and enhanced secretion of the protein employing target cell-tailored secretion signals.
Keywords: clotting factor IX, DNA Transfection, GFP expression, RNA stability, X-linked recessive disorder
Current Genomics
Title: RNA-Based Gene Therapy for Haemophilia B
Volume: 6 Issue: 6
Author(s): M. P. Peppelenbosch, F. Milano, C. V. Ferreira, A. Knapinska, S. H. Diks and C. A. Spek
Affiliation:
Keywords: clotting factor IX, DNA Transfection, GFP expression, RNA stability, X-linked recessive disorder
Abstract: Haemophilia B, a deficiency in clotting factor IX (FIX), occurs in about 1 in 25.000 males. Of these patients, approximately 40% are characterized as having severe haemophilia (FIX below 1% of normal). Although the use of plasma-derived or rFIX has extended the lifespan of these patients, they remain afflicted by a variety of sequelae of the disease. Interestingly, a relatively small increase in the levels of FIX results in a dramatic increase in the quality of life, requiring rFIX substitution only prior to dental and surgical procedures. This latter trait of the disease suggests that gene therapy only needs to achieve modest expression and makes this disease a prime candidate for proof-of-concept of gene therapy. Current protocols for gene therapy entail the risk of malignant transformation. In addition the viral vectors may cause substantial pathology. Hence, the field requires the development of inherently safe gene therapy. Recently, developed protocols have been developed to transduce peripheral blood cells with high efficiency using RNA as a vector. These protocols in which the inherently safe RNA-based gene therapy approach will be validated and implemented for haemophilia B will provide in turn providing important proof-of concept for this type of therapy for more prevalent diseases but requires optimization of this strategy, probably by enhancing RNA stability using artificial nucleotides and modified UTRs, enhanced production of protein by codon usage optimization and the use of multi-cistronic constructs, and enhanced secretion of the protein employing target cell-tailored secretion signals.
Export Options
About this article
Cite this article as:
Peppelenbosch P. M., Milano F., Ferreira V. C., Knapinska A., Diks H. S. and Spek A. C., RNA-Based Gene Therapy for Haemophilia B, Current Genomics 2005; 6 (6) . https://dx.doi.org/10.2174/138920205774483052
DOI https://dx.doi.org/10.2174/138920205774483052 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced AI Techniques in Big Genomic Data Analysis
The thematic issue on "Advanced AI Techniques in Big Genomic Data Analysis" aims to explore the cutting-edge methodologies and applications of artificial intelligence (AI) in the realm of genomic research, where vast amounts of data pose both challenges and opportunities. This issue will cover a broad spectrum of AI-driven strategies, ...read more
Advanced Computational Algorithms and Artificial Intelligence in Clinical Pharmacogenomics
In the era of personalized medicine, understanding the relationship between genetics and drug response is crucial. This issue delves into innovative methodologies, leveraging deep computational analysis and artificial intelligence, to enhance the field of Clinical Pharmacogenomics. The interdisciplinary approach harnesses the power of advanced high-throughput genotyping technologies, sophisticated computational analysis, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Big Data in Cancer Research
Cancer is a significant threat to human life and health, remaining a highly aggressive killer. It is a leading cause of death worldwide and represents a crucial medical issue for humanity. However, in the past decade, the effectiveness of new synthetic anticancer agents has not matched the current clinical speculation. ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Cytokines, Chemokines and Adhesion Molecules in Rheumatoid Arthritis
Current Rheumatology Reviews Aldo-Keto Reductase Family 1 Member B1 Inhibitors: Old Drugs with New Perspectives
Recent Patents on Anti-Cancer Drug Discovery Chlorine, Chlorination By-Products and Their Allergic and Respiratory Health Effects
Current Respiratory Medicine Reviews COX-2 Selective Inhibitors, Carbonic Anhydrase Inhibition and Anticancer Properties of Sulfonamides Belonging to This Class of Pharmacological Agents
Mini-Reviews in Medicinal Chemistry PET Imaging of the Peripheral Benzodiazepine Receptor: Monitoring Disease Progression and Therapy Response in Neurodegenerative Disorders
Current Pharmaceutical Design Oxaliplatin Based Chemotherapy and Concomitant Highly Active Antiretroviral Therapy in the Treatment of 24 Patients with Colorectal Cancer and HIV Infection
Current HIV Research First Inhibitors of the Steroidogenic Enzyme Type 7 17β-Hydroxysteroid Dehydrogenase
Letters in Drug Design & Discovery Functional Genomic Approaches Targeting the Wnt Signaling Network
Current Drug Targets Effective Delivery of Male Contraceptives Behind the Blood-Testis Barrier (BTB) – Lesson from Adjudin
Current Medicinal Chemistry Potential of Taming MicroRNA on Driver Seat to Control Mitochondrial Horses in Breast Carcinoma
MicroRNA Paramutation: Just a Curiosity or Fine Tuning of Gene Expression in the Next Generation?
Current Genomics Zolpidem Therapy for Movement Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Ferritin and Percent Transferrin Saturation Levels Predict Type 2 Diabetes Risk and Cardiovascular Disease Outcomes
Current Diabetes Reviews Computational Approaches on Angiotensin Receptors and Their Ligands: Recent Developments and Results
Current Medicinal Chemistry Recent Advancemnts in Biodegradable Ocular Implants
Current Drug Delivery Targeting the Voltage-Dependent K+ Channels Kv1.3 and Kv1.5 as Tumor Biomarkers for Cancer Detection and Prevention
Current Medicinal Chemistry Various Non-Injectable Delivery Systems for the Treatment of Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Trophoblast Invasion: A Possible Link Between Implantation Deficiencies and Preeclampsia
Current Women`s Health Reviews Recent Approaches in Chemoprevention of Prostate Cancer
Current Cancer Drug Targets Biosafety Considerations Using Gamma-Retroviral Vectors in Gene Therapy
Current Gene Therapy